News Releases

Month Year

Email Alerts

Jul 8, 2013

Insmed to Present at the 8th Annual JMP Securities Healthcare Conference
Jul 1, 2013

ARIKACE Meets Primary Endpoint of Non-Inferiority to TOBI in Phase 3 Clinical Trial in Europe and Canada to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients

ARIKACE Receives Qualified Infectious Disease Product and Fast Track Designations from the U.S. FDA for the Treatment of Non-Tuberculous Mycobacteria Lung Infections
Jun 28, 2013

Insmed to Join the Russell Global(R) and Russell 3000(R) Indexes
Jun 28, 2013

Insmed to Report Top-Line Results From Phase 3 Clinical Trial of ARIKACE to Treat Pseudomonas Aeruginosa in Cystic Fibrosis
May 14, 2013

Insmed Granted Key Composition of Matter Patent Allowance for ARIKACE in Europe
May 13, 2013

Insmed to Present at the UBS Global Healthcare Conference
May 10, 2013

Insmed to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
May 7, 2013

Insmed Reports First Quarter Financial Results
May 1, 2013

Insmed to Host First Quarter 2013 Financial Results Conference Call on Tuesday, May 7, 2013
Apr 18, 2013

Insmed to Present at the 12th Annual Needham Healthcare Conference
Apr 1, 2013

Insmed Appoints Matthew Pauls as Chief Commercial Officer
Mar 28, 2013

ARIKACE Receives Orphan Drug Designation for Treating Infections Caused by Non-Tuberculous Mycobacteria
Mar 27, 2013

Insmed to Present at Future Leaders in the Biotech Industry Conference
Mar 18, 2013

Insmed Reports Fourth Quarter and Full Year 2012 Financial Results
Mar 11, 2013

Insmed to Host Fourth Quarter and Full Year 2012 Financial Results Conference Call on Monday, March 18, 2013
Feb 26, 2013

Insmed to Present at Two Upcoming Investor Conferences
Feb 6, 2013

Insmed to Present at Two Upcoming Healthcare Investor Conferences
Dec 13, 2012

Insmed to Present at 31st Annual J.P. Morgan Healthcare Conference
Nov 13, 2012

Insmed Announces CLEAR-108 Phase 3 Clinical Study of ARIKACE® in Cystic Fibrosis Patients with Pseudomonas Lung Infections Has Completed Target Enrollment
Nov 12, 2012

Insmed To Present At Two Upcoming Investor Conferences
Nov 7, 2012

Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer
Nov 7, 2012

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2012
Oct 24, 2012

Insmed to Host 2012 Third Quarter Earnings Conference Call
Sep 28, 2012

Insmed Announces Pricing of Approximately $26 Million Direct Public Offering
Aug 30, 2012

Insmed to Present at Stifel Nicolaus 2012 Healthcare Conference
Aug 14, 2012

Insmed to Present at 2012 Wedbush PacGrow Life Sciences Management Access Conference
Aug 7, 2012

Insmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012
Aug 6, 2012

Pharmaceutical Industry Veteran Al Altomari Elected To Insmed's Board Of Directors
Aug 2, 2012

Insmed Receives Second Composition Of Matter Patent For ARIKACE®
Jul 30, 2012

Insmed Announces Planned Departure Of Chief Financial Officer
Jul 24, 2012

Insmed to Host 2012 Second Quarter Earnings Conference Call
Jul 10, 2012

Insmed To Present At JMP Securities 7th Annual Healthcare Conference
Jul 2, 2012

Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
Jun 27, 2012

Insmed Announces First Patient Dosed in TARGET-NTM Phase 2 Clinical Trial of ARIKACE® in Patients with Non-Tuberculous Mycobacteria (NTM) Lung Disease
May 30, 2012

Insmed Provides Corporate Update
May 23, 2012

Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
May 16, 2012

Insmed Appoints Donald J. Hayden, Jr. as Executive Chairman
May 8, 2012

Insmed Announces First Quarter 2012 Financial Results
May 7, 2012

Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
Apr 24, 2012

Insmed to Host 2012 First Quarter Earnings Conference Call
Apr 16, 2012

Insmed Announces First Patient Dosed in Pivotal European Phase 3 Clinical Study of ARIKACE® in Cystic Fibrosis Patients with Pseudomonas Lung Infections
Mar 13, 2012

Insmed Announces Fourth Quarter and Full-Year 2011 Financial Results
Feb 28, 2012

Insmed to Host Fourth Quarter and 2011 Year-End Earnings Conference Call
Feb 10, 2012

Insmed Incorporated Provides Update on Clinical Program for ARIKACE®
Jan 20, 2012

Insmed Incorporated Provides Corporate Update
Nov 14, 2011

Insmed to Present at Lazard Capital Markets 8th Annual Healthcare Conference
Nov 8, 2011

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2011
Oct 25, 2011

Insmed to Host 2011 Third Quarter Earnings Conference Call
Oct 24, 2011

Insmed Incorporated Provides Regulatory Update on ARIKACE® in Non-Tuberculous Mycobacteria Indication
Oct 10, 2011

Insmed Incorporated Provides Regulatory Update

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

View the latest Insmed Investor Presentation

Download

Our Global Company

Current Clinical Trials

Our Research Team

Our Global Company

Current Clinical Trials

Our Research Team

Footer